Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

RxSpan MD vs Vytora Health

By GLP-1 ScorecardUpdated

RxSpan MD
Site position #4

Higher score

Vytora HealthFactor scores not reassessed.
Site position #90

Lower score

Score comparison

RxSpan MD has the higher recorded score — 84.3/100 to 72.3/100.

RxSpan MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. RxSpan MD's live catalog lists brand-name GLP-1 drugs, while its homepage also advertises compounded plans; confirm the actual product and total price before enrolling.

Before you choose

RxSpan MD does not publish a semaglutide price, so its RxSpan MD review sets out what it does disclose, while the Vytora Health review explains the conditions attached to Vytora Health's figure. The semaglutide cost page compares published rates across the field. Ask RxSpan MD for a written total before treating either one as the cheaper choice.

If neither one fits, RxSpan MD vs Wellorithm and Synergy Rx vs Vytora Health compare each of them with another graded program, and the list of alternatives to RxSpan MD ranks the programs closest to RxSpan MD on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueRxSpan MD +27
86
59
Dose & formulationRxSpan MD +4
89
85
Clinical oversightVytora Health +8
88
96
Labs & monitoringRxSpan MD +28
83
55
FulfillmentVytora Health +7
89
96
Contract termsRxSpan MD +33
53
20
RxSpan MD · top barVytora Health · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricRxSpan MDVytora Health
WeighScore84.3/10072.3/100
GradeBC
Site position#4#90
SemaglutideCurrent compounded quote unconfirmed$179 for one month (compounded)
TirzepatideCurrent compounded quote unconfirmed$249 for one month (compounded)
CoverageConfirm treatment availability during intakeAll 50 states and D.C. advertised; availability varies by service
Brand-name accessYesYes
Oral / sublingualNot confirmedNot confirmed
RxSpan MD

Site position #4 · B

Strengths

  • Current public catalog lists Ozempic, Wegovy, Mounjaro and Zepbound
  • Public terms describe independent healthcare providers
  • Homepage describes messaging and care-team appointments

What to consider

  • Homepage advertises compounded plans that the current catalog did not substantiate
  • Current oral GLP-1 availability is unconfirmed
  • Prior compounded prices are not a current quote; selected dose, supply, pharmacy and fee inclusions need confirmation
  • Public terms do not establish unused prepaid-treatment refund amounts
Vytora Health

Site position #90 · C

Factor scores not reassessed.

Strengths

  • Publishes the full three-month charge as well as the monthly equivalent
  • Advertises physician consultation, supplies and shipping in the compounded plan price
  • Names the clinical groups and lists partner pharmacies

What to consider

  • Plans renew automatically and the public terms leave the cancellation cutoff unclear
  • Prescription sales are final under the published refund policy
  • Confirm service and pharmacy availability for your state

Featured provider

RxSpan MD

RxSpan MD scores 84.3/100 (B). RxSpan MD's live catalog lists brand-name GLP-1 drugs, while its homepage also advertises compounded plans; confirm the actual product and total price before enrolling.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard